



Contact:

David Waldman or Justyna Gudaszewska

Crescendo Communications, LLC

Email: mmd@crescendo-ir.com

Tel: +48 693 354 580

Milestone Scientific, The Licensor of Milestone Medical Inc. Receives Notice of Allowance for New U.S. Patent

LIVINGSTON, NJ, November 5, 2018 -- Milestone Medical Inc. (WAR:MMD) today announced that Milestone Scientific Inc., the licensor and the majority shareholder of Milestone Medical Inc. has received a Notice of Allowance for a key patent from the U.S. Patent and Trademark Office. The patent covers the method and apparatus for performing a peripheral nerve block (PNB).

Dr. Mark Hochman, D.D.S., Inventor and Clinical Director of Milestone Scientific Inc., stated, "Our computer-controlled systems with proprietary *DPS* Dynamic Pressure Sensing technology® are designed to make all types of injections precise, efficient, and virtually painless. This patent will further expand our intellectual property portfolio into PNB procedures. PNBs are a form of regional anesthesia that has significantly increased in use for the treatment of trauma and surgical procedures as well as for postoperative and nonsurgical analgesia. PNBs offer distinct advantages over general or neuraxial anesthesia as PNBs have less of the risks, complications and residual post-operative side effects of general anesthesia, resulting in quicker post-operative recovery time. Leveraging this patent to develop an instrument that is optimized specifically for PNB in the future will allow medical professionals to precisely control the numerous critical parameters of performing a PNB procedure. I believe it will improve safety, efficiency and efficacy, thus resulting in an improved quality of care for patients."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical device company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary *DPS* Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2017. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

#